From flop to franchise: Cyberpunk 2077 is getting a sequel
Cyberpunk 2077 developer CD Projekt Red announced in an earnings call Wednesday that the company is at work on a follow-up to the futuristic role-playing title, which was released in late 2020 and universally criticized for being unfinished, glitchy and at times unplayable.
CD Projekt Red said that the conceptual phase is complete and pre-production has begun on the 'next big game set in the Cyberpunk universe,' which it is calling Cyberpunk 2 for now. The company expects the game's development to take four to five years, but that number could shift as the project gets underway.
The redemption story is a striking change of fate for Cyberpunk 2077, which not longer ago was doomed to languish in video game lore as one of the greatest failures of all-time.
Cyberpunk's skyscraper-high launch expectations
For a time, Cyberpunk 2077 appeared destined to become gamer shorthand for a much-hyped game that over-promises and under-delivers to the extreme. The backlash over Cyberpunk 2077' s likely premature launch was so severe that many platforms hosting the game's download began issuing refunds to appease unhappy players, with Sony even going as far as taking the game out of the PlayStation store.
At the time of its initial release, hype for Cyberpunk 2077 was sky high. Developer CD Projekt Red was widely lauded for its hit The Witcher 3: Wild Hunt, a sprawling open world RPG famous for rich narrative storytelling. It didn't help that Cyberpunk 2077's development budget topped $300 million, making it one of the most expensive games ever made.
A very expensive makeover
Instead of calling Cyberpunk 2077 a flop and moving on, CD Projekt Red kept chipping away at the game, issuing improvements to stabilize its performance, deepen combat and paint richer stories in its glowing Tokyo-esque fictional metropolis, Night City.
Cyberpunk 2077 joins only a handful of games including Final Fantasy XIV and No Man's Sky that have completely re-written their own histories after failing spectacularly. For Cyberpunk 2077 and those games alike, the modern model of live-service games – games that evolve and get updates over time, sometimes through paid content – made the comeback stories possible. After their initial missteps, the teams behind all of these games spent years winning back players and rebuilding their communities, earning a lot of respect in the process.
Cyberpunk 2077's turnaround wasn't cheap. The company poured north of $100 million in additional resources into the game after its launch, putting out a major 'large-scale' expansion called Phantom Liberty, starring actor Idris Elba, who joined Keanu Reeves on the game's A-list voice acting cast. In its earnings call, CD Projekt Red announced that the expansion has now sold more than 10 million copies.
Fast forward four years and the team behind the former failure clawed their reputation back so successfully that Steam's user reviews now rate Cyberpunk 2077 as ' overwhelmingly positive ' – an outcome that would have been impossible to imagine back in the game's dark days.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on August 7, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its second quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days. About Ascendis Pharma A/S Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit to learn more. Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' ability to apply its TransCon technology platform to make a meaningful difference for patients and (ii) Ascendis' application of TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. © July 2025 Ascendis Pharma A/S. Investor Contacts: Media Contact: Sarada Weerasinghe Melinda Baker Ascendis Pharma Ascendis Pharma ir@ media@ Patti Bank ICR Healthcare +1 (415) 513-1284
Yahoo
23 minutes ago
- Yahoo
Shell Keeps Buyback Despite Profit Drop
Shell (NYSE:SHEL) held its $3.5 billion buyback and beat Q2 estimates even as profit slid on softer prices. Adjusted Q2 earnings fell to $4.26 billion from $5.58 billion in Q1, but that still topped the $3.74 billion consensus, and the company kept its share repurchase pace for Q3. Warning! GuruFocus has detected 4 Warning Sign with AMZN. Integrated gas earnings dropped 30% to $1.74 billion and upstream slipped 25% to $1.73 billion amid the lower price backdrop, yet Shell managed to lift free cash by $1.2 billion for the quarter and shave another $800M in structural costs in H1 bringing total savings since 2022 to $3.9 billion. The firm's balance sheet shows tension with net debt ticking up to $43.2 billion from $41.5 billion in Q1 even as RBC Capital's Biraj Borkhataria and Adnan Dhanani praised the strong marketing division and saw the sustained buyback as justified given Shell's relative strength versus peers. Also, Hargreaves Lansdown's Derren Nathan warned that while the quarter was resilient, persistent debt increases could erode confidence if the trend stays the same. This article first appeared on GuruFocus.
Washington Post
25 minutes ago
- Washington Post
Dozens of countries with no deals face higher tariffs as trade deadline nears
WASHINGTON — Numerous countries around the world are facing the prospect of much higher duties on their exports to the United States on Friday, a potential blow to the global economy, because they haven't yet reached a trade deal with the Trump administration. Some of the United States' biggest trading partners have reached agreements , or at least the outlines of one, including the European Union , the United Kingdom , and Japan . Even so, those countries face much higher tariffs than were in effect before Trump took office. And other large trading partners — most notably China and Mexico — received an extension to keep negotiating and won't be hit with new duties Friday, but they will likely end up paying more. President Donald Trump intends the duties to bring back manufacturing to the United States, while also forcing other countries to reduce their trade barriers to U.S. exports. Trump argues that foreign exporters will pay the cost of the tariffs, but so far economists have found that most are being paid by U.S. companies. And measures of U.S. inflation have started to tick higher as prices of imported goods, such as furniture, appliances, and toys rise. For those countries without an agreement, they could face duties of as much as 50%, including on large economies such as Brazil, Canada, Taiwan, and India. Many smaller countries are also on track to pay more, including South Africa, Sri Lanka, Bangladesh, and even tiny Lesotho . The duties originated from Trump's April 2 'Liberation Day' announcement that the United States would impose import taxes of up to 50% on nearly 60 countries and economies, including the 27-nation European Union. Those duties, originally scheduled for April 9, were then postponed twice, first to July 9 and then Aug. 1. As of Thursday afternoon, White House representatives — and Trump himself — insisted that no more delays were possible. White House press secretary Karoline Leavitt said Thursday that Trump 'at some point this afternoon or later this evening' will sign an order to impose new tariff rates starting midnight on Friday. Countries that have not received a prior letter on tariffs from Trump or negotiated a trade framework will be notified of their likely tariff rates, Leavitt said, either in the form of a letter or Trump's executive order. At least two dozen countries were sent letters setting out their tariff rates. On Wednesday, Trump said on his social media platform Truth Social, 'THE AUGUST FIRST DEADLINE IS THE AUGUST FIRST DEADLINE — IT STANDS STRONG, AND WILL NOT BE EXTENDED.' In a flurry of last minute deal-making, the Trump has been announcing agreements as late as Thursday, but they are largely short on details. On Thursday, the U.S. and Pakistan reached a trade agreement expected to allow Washington to help develop Pakistan's largely untapped oil reserves and lower tariffs for the South Asian country. And on Wednesday, Trump announced a deal with South Korea that would impose 15% tariffs on goods from that country. That is below the 25% duties that Trump threatened in April. Agreements have also been reached with the European Union, Pakistan , Indonesia, Vietnam, the Philippines , and the United Kingdom. The agreement with the Philippines barely reduced the tariff it will pay, from 20% to 19%. The exact number of countries facing higher duties isn't clear, but the majority of the 200 have not made a deal. Trump has already slapped large duties on Brazil and India even before the deadline was reached. In the case of Brazil, Trump signed an executive order late Wednesday imposing a 50% duty on imports, though he exempted several large categories, including aircraft, aluminum, and energy products. Trump is angry at Brazil's government because it is prosecuting its former president, Jair Bolsonaro, for attempting to overturn his election loss in 2022. Trump was indicted on a similar charge in 2023. While Trump has sought to justify the widespread tariffs as an effort to combat the United States' chronic trade deficits, the U.S. actually has a trade surplus with Brazil — meaning it sells more goods and services to Brazil than it buys from that country. Late Wednesday, Trump said that India would pay a 25% duty on all its exports, in part because it has continued to purchase oil from Russia. On Thursday, the White House said it had extended the deadline to reach a deal with Mexico for another 90 days, citing the complexity of the trade relationship, which is governed by the trade agreement Trump reached when he updated NAFTA in his first term. ___ AP Writers Josh Boak and Wyatte Grantham-Philipps contributed to this report.
